How much revenue does Shanghai Yizhong Pharmaceutical make?

Shanghai Yizhong Pharmaceutical reported 173.53 million CNY in revenue for fiscal year 2024, down 51.8% from 360.25 million CNY in fiscal year 2023. In Q2 2025 revenue was 89.28 million CNY.

What companies are similar to Shanghai Yizhong Pharmaceutical?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Betta Pharmaceuticals Co., Ltd. (300558.SZ), Shenzhen Chipscreen Biosciences Co., Ltd. (688321.SS), InventisBio Co., Limited (688382.SS), Jiangsu Yahong Meditech Co., Ltd. (688176.SS).

Shanghai Yizhong Pharmaceutical Co., Ltd. (688091.SS) Stock

About Shanghai Yizhong Pharmaceutical Co., Ltd.

Shanghai Yizhong Pharmaceutical Co., Ltd. engages in the research and development of anti-tumor drugs and related products in China. The company offers paclitaxel polymer micelles for injection for the treatment of non-small cell lung cancer, as well as various types of cancer, including esophageal cancer, gastric cancer, nasopharyngeal carcinoma, pancreatic cancer, breast cancer, and gynecologica...

At a glance

Shanghai Yizhong Pharmaceutical reported revenue of 173.53 million CNY for fiscal year 2024, down 51.8% from fiscal year 2023, and net income of 6.98 million CNY. In Q2 2025 (the quarter ended June 30, 2025) revenue was 89.28 million CNY, up 67.8% from a year before.

Figures from company filings; latest fiscal year ended December 31, 2024.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.